Alembic Pharmaceuticals Limited — Others, 06-05-2025: Change in Auditors

Alembic Pharmaceuticals has announced a board meeting in which it approved the financial results for the quarter and half-year ended 31st March 2025. The Board proposed a dividend of Rs. 11 per share (550%) subject to shareholder approval. Consolidated revenue was Rs. 6,672 Cr with a net profit of Rs. 583 Cr, while standalone revenue stood at Rs. 6,033 Cr with a net profit of Rs. 503 Cr. Earnings per share were Rs. 29.68 (consolidated) and Rs. 25.60 (standalone). Operations have fully resumed after flood disruptions, and the company maintains a moderate debt-equity ratio near 0.22, reflecting financial stability. New statutory and secretarial auditors were appointed for a five-year term.